

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6: <b>C12N 15/16, C07K 14/375, A61K 38/22, C12N 15/70, 1/21 // (C12N 1/21, C12R 1:19)</b>		A1	(11) International Publication Number: <b>WO 97/24441</b> (43) International Publication Date: <b>10 July 1997 (10.07.97)</b>
(21) International Application Number: <b>PCT/US96/20718</b>		(74) Agent(s): DRINGER, Ginger, R. et al.; Genentech, Inc., 460 Point San Bruno Boulevard, South San Francisco, CA 94080-4990 (US).	
(22) International Filing Date: <b>19 December 1996 (19.12.96)</b>		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KR, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, ARIPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG)	
(30) Priority Data: 08/579,494 27 December 1995 (27.12.95) US 08/667,184 20 June 1996 (20.06.96) US		(60) Parent Application or Grant (63) Related by Continuation US 08/667,184 (CIP) Filed on 20 June 1996 (20.06.96)	
(71) Applicant (for all designated States except US): GENENTECH, INC. (US/US); 460 Point San Bruno Boulevard, South San Francisco, CA 94080 (US).			
(72) Inventors; and (73) Inventors/Applicants (for US only): DE SAUVAGE, Frederic J. (BE/US); 166 Beach Park Boulevard, Foster City, CA 94404 (US). LEVIN, Nancy (US/US); 900 Ashbury Street #D, San Francisco, CA 94117 (US). VANDLEN, Richard L. (US/US); 1015 Haynes Road, Hillsborough, CA 94010 (US).			

(54) Title: OB PROTEIN DERIVATIVES HAVING PROLONGED HALF-LIFE

(57) Abstract

The present invention concerns long half-life derivatives of the obesity protein OB. The invention specifically concerns OB protein immunoglobulin chimeras and polyethylene glycol (PEG)-OB derivatives, which have extended half-life as compared to the corresponding native OB proteins. The invention further relates to methods for appetite and/or weight reduction and for treating other physiological conditions by using the long half-life derivatives of OB.

BEST AVAILABLE COPY